# US 2013/0157946 A1 · Neurotrophic peptides > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0157946 A1 - Document ID: US20130157946A1 - Status: Published application - Kind: A1 - Application number: 13/676,649 - Filed: 2012-11-14 - Published: 2013-06-20 - Earliest claimed: 2007-03-16 - Assignees: The Research Foundation for Mental Hygiene, Inc. - Inventors: Khalid Iqbal; Inge Grundke-Iqbal - Web page: https://patentgrep.com/patent/US20130157946A1 ## CPC - C07K 5/1021: {with the first amino acid being acidic} - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3} - C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala} - C07K 5/101: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu} - C07K 7/06: having 5 to 11 amino acids - C07K 14/475: Growth factors; Growth regulators - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease. ## Claims ### Claim 1 A method of treating a subject having Alzheimer's disease comprising the step of administering a therapeutic amount of at least a portion of a neurotrophic peptide having the amino acid sequence VGDGGLFEKKL (SEQ ID NO: 1). ### Claim 2 (depends on 1) The method of claim 1, wherein said neurotrophic peptide comprises GDGGLFEK (SEQ ID NO: 5). ### Claim 3 (depends on 1) The method of claim 1, wherein said neurotrophic peptide comprises GLFEKKLW (SEQ ID NO: 6). ### Claim 4 (depends on 1) The method of claim 1, wherein said neurotrophic peptide comprises VGDG (SEQ ID NO: 7). ### Claim 5 (depends on 1) The method of claim 1, wherein said neurotrophic peptide comprises GDGG (SEQ ID NO: 8). ### Claim 6 (depends on 1) The method of claim 1, wherein said neurotrophic peptide comprises DGGL (SEQ ID NO: 9). ### Claim 7 (depends on 1) The method of claim 1, wherein said neurotrophic peptide comprises GGLF (SEQ ID NO: 10). ### Claim 8 (depends on 1) The method of claim 1, wherein said neurotrophioc peptide is administered peripherally. ### Claim 9 (depends on 1) The method of claim 1, wherein said neurotrophioc peptide is administered subcutaneously. ### Claim 10 (depends on 1) The method of claim 1, wherein said neurotrophioc peptide is administered orally. ### Claim 11 (depends on 1) The method of claim 1, wherein said neurotrophioc peptide is administered intraperitoneally. ### Claim 12 A method of treating a subject having Alzheimer's disease comprising the step of administering a therapeutic amount of at least a portion of a neurotrophic peptide having the amino acid sequence VGDGGLFEKKL (SEQ ID NO: 1) bound to an adamantane building block. ### Claim 13 (depends on 12) The method of claim 12, wherein said adamantane building block is bound to a C-terminus of said neurotrophic peptide. ### Claim 14 (depends on 12) The method of claim 12, wherein another adamantane building block is bound to an N-terminus of said neurotrophic peptide. ### Claim 15 (depends on 12) The method of claim 12, wherein said adamantane building block comprises 3-aminoadamantane-1-carboxylic acid. ### Claim 16 (depends on 12) The method of claim 12, wherein said neurotrophic peptide comprises DGGL (SEQ ID NO: 9). ### Claim 17 (depends on 12) The method of claim 12, wherein said neurotrophic peptide bound to said adamantane building block comprises the sequence Ac-DGGLAG-NH2 (SEQ ID NO: 12). ### Claim 18 (depends on 12) The method of claim 12, wherein said neurotrophic peptide bound to said adamantane building block comprises the sequence Ad-CO-DGGLAG-NH2 (SEQ ID NO: 13).